Tirzepatide (GLP-1/GIP)
A dual-incretin compound studied in metabolic research.
Overview
Tirzepatide is a synthetic dual agonist that interacts with both the GLP-1 and GIP incretin receptors. In research literature it is studied in the context of metabolic and appetite-regulation pathways. It is one of the most extensively referenced dual-incretin compounds in the metabolic research category.
Referenced research ranges
2.5–15 mg, once weekly — research protocols reference gradual titration across weeks
Reconstitution default
10 mg in 2 mL yields 5 mg/mL; a 2.5 mg reference dose is 0.5 mL (50 units on a U-100 syringe).
Storage
Store lyophilized vials refrigerated; refrigerate after reconstitution and protect from light.
Considerations
- Long half-life, so research protocols reference once-weekly administration.
- Literature commonly references stepwise titration rather than a fixed amount.
- Reconstituted peptide is temperature-sensitive and light-sensitive.
Log doses, get reminders, and run the calculator in PepSensei.
PepSensei is an educational reference tool only. Nothing in this library is medical advice, and none of it is intended to diagnose, treat, cure, or prevent any condition. All figures — including dose ranges, half-lives, and reconstitution examples — are commonly-cited values drawn from published research literature and are provided strictly for reference and general education in a research context. They are not protocols, recommendations, or instructions. Always consult a licensed medical professional before making any decision related to your health.